The clinical use of BonAlive® granules in trauma surgery is supported by a long-term randomised prospective trial with an 11-year follow-up in patients with tibial plateau fractures. The results from the trial clearly showed that the long-term performance of BonAlive® granules is comparable to autograft.
BonAlive® granules is a unique bone graft substitute that inhibits bacterial growth on a vast number of bacterial species that are related to orthopaedic complications, including e.g. MRSA.
BonAlive® granules produces a high but balanced local bone turnover by stimulating new bone formation through osteostimulation*.
For further details see references.